This article names the company behind Wegovy, situates it within that maker’s semaglutide and liraglutide lineup and approval dates, and contrasts the two dominant GLP-1 manufacturers. It also summarizes their shared safety warnings and explains the genetic context that precedes any protocol decision.

This article identifies the company behind Ozempic, walks through its broader GLP-1 portfolio and approval timeline, compares its molecular strategy with its main competitor, outlines the class safety profile they share, and explains the genetic context upstream of every product.

Rybelsus (oral semaglutide) is FDA-approved for type 2 diabetes only — not for weight loss. See the real PIONEER weight numbers, the ~$998/month cash price, why insurance rarely covers off-label use, and how PlexusDx Semaglutide Oral ($289/mo+) and the Microdose GLP-1 Protocol ($129/mo) compare on cost and dose flexibility.

Ozempic is one product in Novo Nordisk's broader GLP-1 lineup. This guide places it in context: the full portfolio and its FDA-approved indications, how it compares to Eli Lilly's strategy, the class safety profile shared across manufacturers, and the genetic variables upstream of every GLP-1 compound.

Wegovy is Novo Nordisk's semaglutide product approved for chronic weight management. This guide situates it within the full portfolio, compares Novo Nordisk's strategy to Eli Lilly's, outlines the class safety profile shared across manufacturers, and explains the genetic variables that sit upstream of every GLP-1 compound.